Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome

Three hundred patients with symptomatic, locally advanced or metastatic NSCLC not requiring immediate radiotherapy were enrolled into this randomized multicentre trial comparing gemcitabine + BSC vs BSC alone. Patients allocated gemcitabine received 1000 mg/m(2)on days 1, 8 and 15 of a 28-day cycle,...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, H, Hopwood, P, Stephens, R J, Thatcher, N, Cottier, B, Nicholson, M, Milroy, R, Maughan, T S, Falk, S J, Bond, M G, Burt, P A, Connolly, C K, McIllmurray, M B, Carmichael, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374661/
https://www.ncbi.nlm.nih.gov/pubmed/10945489
http://dx.doi.org/10.1054/bjoc.2000.1307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374661/
https://www.ncbi.nlm.nih.gov/pubmed/10945489
http://dx.doi.org/10.1054/bjoc.2000.1307

Ejemplares similares